Dermatological uses for ivermectin

The patient’s report was accurate.

Ivermectin is used as a strong anti-inflammatory esp for scabies and lice resistant to other interventions.

Zargari O, Aghazadeh N, Moeineddin F. Clinical applications of topical ivermectin in dermatology. Dermatol Online J. 2016 Sep 15;22(9):13030/qt1kq4p7pp. PMID: 28329606.

see also

Mathachan SR, Sardana K, Khurana A. Current Use of Ivermectin in Dermatology, Tropical Medicine, and COVID-19: An Update on Pharmacology, Uses, Proven and Varied Proposed Mechanistic Action. Indian Dermatol Online J. 2021;12(4):500-514. Published 2021 Jul 14. doi:10.4103/idoj.idoj_298_21

Ivermectin is a broad-spectrum antiparasitic drug with anti-inflammatory, anti-viral, anti-bacterial, and anti-tumor effects. In this review, we discuss the history, pharmacology, multimodal actions, indications in dermatology and tropical medicine, therapeutic and prophylactic use of ivermectin in COVID-19, safety, adverse effects, special considerations, and drug interactions of ivermectin.

JT

Joseph (Joe) E. Thornton, M.D., DFAPA
Adjunct Clinical Associate Professor, Psychiatry
University of Florida College of Medicine
joethornton@ufl.edu

CONFIDENTIALITY NOTIFICATION: Please be advised! This e-mail message, including any attachments, has been created explicitly for the sole use of the intended recipient(s) and may contain confidential and privileged information. The materials in this message are private and may contain Protected Healthcare Information or other information of a sensitive nature. If you are not the intended recipient, be advised that any unauthorized use, disclosure, copying or the taking of any action in reliance on the contents of this information is strictly prohibited. If you have received this email in error, please immediately notify the sender via telephone or return mail. Any unauthorized review, use, disclosure, or distribution of such information is prohibited and will be upheld under the discretion of Federal and State law. If you have received this e-mail message in error and are not an intended recipient, please contact the sender via reply e-mail or phone and destroy all copies of the original message. Pursuant to ‘ FS 766.101, FS 395.0193, FS 395.0197, FS 766.1016 and other Statutes, this document is privileged and confidential. It is not subject to discovery. Please do NOT copy or release.